Hypermethylation of PD-L1 at K162 leads to anti-PD-L1 and anti-PD-1 treatment insensitivity, acting as an adverse predictive factor for these treatments in NSCLC patients [171]. Here, CD274 is linked to non-small cell lung carcinoma.